{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:41:46Z","timestamp":1781682106841,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024879","name":"Janssen Australia","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100024879","name":"Janssen Australia","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100024879","name":"Janssen Australia","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100024879","name":"Janssen Australia","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Listening to patient voices is critical, in terms of how people experience their condition as well as their treatment preferences. This research explored the patient journey, therapy attributes and goals among treatment experienced adults with chronic lymphocytic leukemia (CLL). We sought to understand patient experiences, needs and expectations to identify areas for improvement of treatment and care delivery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two online surveys were developed for completion by CLL patients. In Stage 1, participants completed a best-worst scaling (BWS) task to evaluate eleven previously validated healthcare journey moments that matter (MTM). Responses were used to generate the patient experience index (PEI) score. In Stage 2, participants completed a survey that included both a discrete choice experiment (DCE) to assess drivers of treatment preferences by evaluating the relative attribute importance (RAI) of seven features and a BWS exercise which explored long-term treatment goals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-five patients completed Stage 1 and thirty patients Stage 2. Treatment experience was balanced between oral and intravenous medication. The most important\/least satisfied MTM were treatment effectiveness, access to support and other treatments as well as monitoring progress. The median PEI score was 66.2 (out of 100). DCE results demonstrated that patients most value treatments for CLL that are associated with prolonged progression free survival (PFS; RAI: 24.6%), followed by treatments that have a lower risk of severe side effects and lower out-of-pocket costs (RAI: 19.5%, 17.4%, respectively). The remainder of the weight in decision making (38.5%) was split between the remaining attributes, namely \u2018mild to moderate side effects\u2019 (13.4%), \u2018long-term risks\u2019 (12.2%), type of treatment (i.e., oral, IV or a combination of oral and IV; 8.7%) and treatment duration (i.e., ongoing versus fixed; 4.2%). Patients preferred oral to intravenous therapy. The most valued long-term treatment goal was to be physically healthy, followed by living a long life, spending time with family\/friends, and avoiding hospitalization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Treatment experienced patients with CLL are focused on receiving effective, safe therapies and value long PFS. Consideration and discussion of other attributes, such as once daily dosing, oral only medication, out-of-pocket costs and access to support services may affect patient treatment choices and ultimately enhance their healthcare experience and outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12589-9","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:03:57Z","timestamp":1720706637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Understanding the experience, treatment preferences and goals of people living with chronic lymphocytic leukemia (CLL) in Australia"],"prefix":"10.1186","volume":"24","author":[{"given":"Simon","family":"Fifer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Godsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masa","family":"Lasica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecily","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Smeaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Winton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"McGeachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"20","key":"12589_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"key":"12589_CR2","unstructured":"Cancer in Australia. 2021 [https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-in-australia-2021\/summary]."},{"issue":"9","key":"12589_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"S Sharma","year":"2019","unstructured":"Sharma S, Rai KR. Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options. Cancer. 2019;125(9):1432\u201340.","journal-title":"Cancer"},{"issue":"6","key":"12589_CR4","doi-asserted-by":"publisher","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","volume":"20","author":"WG Wierda","year":"2022","unstructured":"Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, et al. NCCN Guidelines(R) insights: chronic lymphocytic Leukemia\/Small lymphocytic lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022;20(6):622\u201334.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"12589_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41408-022-00756-9","volume":"12","author":"PJ Hampel","year":"2022","unstructured":"Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022;12(11):161.","journal-title":"Blood Cancer J"},{"issue":"6","key":"12589_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger JA. Bruton tyrosine kinase inhibitors: Present and Future. Cancer J. 2019;25(6):386\u201393.","journal-title":"Cancer J"},{"key":"12589_CR7","doi-asserted-by":"crossref","unstructured":"Smolej L, Vod\u00e1rek P, \u00c9csiov\u00e1 D, \u0160imkovi\u010d M. Chemoimmunotherapy in the first-line treatment of chronic lymphocytic leukaemia: dead yet, or alive and kicking? Cancers (Basel) 2021;13(13):3134.","DOI":"10.3390\/cancers13133134"},{"key":"12589_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.leukres.2015.11.006","volume":"40","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Eriksson J, Ireland S, Musingarimi P, Jackson C, Tweats E, Gaudig M. Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: a conjoint analysis. Leuk Res. 2016;40:17\u201323.","journal-title":"Leuk Res"},{"issue":"24","key":"12589_CR9","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/bloodadvances.2017007294","volume":"1","author":"C Mansfield","year":"2017","unstructured":"Mansfield C, Masaquel A, Sutphin J, Weiss E, Gutierrez M, Wilson J, Boeri M, Li J, Reyes C. Patients\u2019 priorities in selecting chronic lymphocytic leukemia treatments. Blood Adv. 2017;1(24):2176\u201385.","journal-title":"Blood Adv"},{"issue":"1","key":"12589_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jgo.2019.03.010","volume":"11","author":"C Boqu\u00e9","year":"2020","unstructured":"Boqu\u00e9 C, Abad MR, Agust\u00edn MJ, Garc\u00eda-Go\u00f1i M, Moreno C, Gab\u00e1s-Rivera C, Granados E, Castro-G\u00f3mez A, Pardo C, Liz\u00e1n L. Treatment decision-making in chronic lymphocytic leukaemia: key factors for healthcare professionals. PRELIC study. J Geriatr Oncol. 2020;11(1):24\u201330.","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"12589_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in Health Economics: past, Present and Future. PharmacoEconomics. 2019;37(2):201\u201326.","journal-title":"PharmacoEconomics"},{"issue":"7","key":"12589_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40273-017-0506-4","volume":"35","author":"E Lancsar","year":"2017","unstructured":"Lancsar E, Fiebig DG, Hole AR. Discrete choice experiments: a guide to Model Specification. Estimation Softw PharmacoEconomics. 2017;35(7):697\u2013716.","journal-title":"Estimation Softw PharmacoEconomics"},{"issue":"9","key":"12589_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-022-01167-1","volume":"40","author":"IL Hollin","year":"2022","unstructured":"Hollin IL, Paskett J, Schuster ALR, Crossnohere NL, Bridges JFP. Best-worst scaling and the prioritization of objects in Health: a systematic review. PharmacoEconomics. 2022;40(9):883\u201399.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"12589_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JF. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research practices Task Force. Value Health. 2013;16(1):3\u201313.","journal-title":"Value Health"},{"key":"12589_CR15","doi-asserted-by":"crossref","unstructured":"Burke PF, Rose J, Fifer S, Masters D, Kuegler S, Cabrera A. A new subjective well-being index using anchored best-worst scaling. Soc Sci Res 2024 May;120:103013.","DOI":"10.1016\/j.ssresearch.2024.103013"},{"issue":"4","key":"12589_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. Conjoint Analysis Applications in Health; a Checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"key":"12589_CR17","unstructured":"Patient Preference Information. \u2013 Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders [https:\/\/www.fda.gov\/media\/92593\/download]."},{"issue":"5","key":"12589_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/01441640902827623","volume":"29","author":"JM Rose","year":"2009","unstructured":"Rose JM, Bliemer MC. Constructing efficient stated choice experimental designs. Transp Reviews. 2009;29(5):587\u2013617.","journal-title":"Transp Reviews"},{"issue":"4","key":"12589_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, MJ IJ, Bridges JF. Statistical methods for the analysis of Discrete Choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health"},{"key":"12589_CR20","doi-asserted-by":"crossref","unstructured":"Hensher D, Rose J, Greene W. Applied choice analysis: a primer. Cambridge University Press; 2015.","DOI":"10.1017\/CBO9781316136232"},{"issue":"4","key":"12589_CR21","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s10067-019-04843-4","volume":"39","author":"KA Ho","year":"2020","unstructured":"Ho KA, Acar M, Puig A, Hutas G, Fifer S. What do Australian patients with inflammatory arthritis value in treatment? A discrete choice experiment. Clin Rheumatol. 2020;39(4):1077\u201389.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"12589_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/s12913-018-3484-0","volume":"18","author":"S Fifer","year":"2018","unstructured":"Fifer S, Rose J, Hamrosi KK, Swain D. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. BMC Health Serv Res. 2018;18(1):675.","journal-title":"BMC Health Serv Res"},{"key":"12589_CR23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2147\/PPA.S366522","volume":"16","author":"S Fifer","year":"2022","unstructured":"Fifer S, Keen B, Newton R, Puig A, McGeachie M. Understanding the Treatment Preferences of People Living with Schizophrenia in Australia; a patient Value Mapping Study. Patient Prefer Adherence. 2022;16:1687\u2013701.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"12589_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","volume":"12","author":"JM Gonzalez","year":"2019","unstructured":"Gonzalez JM. A guide to Measuring and Interpreting Attribute Importance. Patient. 2019;12(3):287\u201395.","journal-title":"Patient"},{"issue":"1","key":"12589_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12885-020-07018-6","volume":"20","author":"SJ Fifer","year":"2020","unstructured":"Fifer SJ, Ho KA, Lybrand S, Axford LJ, Roach S. Alignment of preferences in the treatment of multiple myeloma - a discrete choice experiment of patient, carer, physician, and nurse preferences. BMC Cancer. 2020;20(1):546.","journal-title":"BMC Cancer"},{"issue":"6","key":"12589_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hec.1739","volume":"21","author":"J Coast","year":"2012","unstructured":"Coast J, Al-Janabi H, Sutton EJ, Horrocks SA, Vosper AJ, Swancutt DR, Flynn TN. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012;21(6):730\u201341.","journal-title":"Health Econ"},{"issue":"1","key":"12589_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-022-01198-8","volume":"41","author":"S Jiang","year":"2023","unstructured":"Jiang S, Ren R, Gu Y, Jeet V, Liu P, Li S. Patient preferences in targeted pharmacotherapy for cancers: a systematic review of Discrete Choice experiments. PharmacoEconomics. 2023;41(1):43\u201357.","journal-title":"PharmacoEconomics"},{"issue":"9","key":"12589_CR28","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1097\/HS9.0000000000000771","volume":"6","author":"L Laurenti","year":"2022","unstructured":"Laurenti L, Gaidano G, Mauro FR, Molica S, Pasqualetti P, Scarf\u00f2 L, Ghia P. What are the attributes prioritized in the choice of Therapy in Chronic lymphocytic leukemia? A patient-physician cross-matching analysis of a Discrete Choice Experiment. Hemasphere. 2022;6(9):e771.","journal-title":"Hemasphere"},{"key":"12589_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PPA.S289139","volume":"15","author":"H Le","year":"2021","unstructured":"Le H, Ryan K, Wahlstrom SK, Maculaitis MC, Will O, Mulvihill E, LeBlanc TW. Oncologist and patient preferences for Novel agents in First-Line treatment for chronic lymphocytic leukemia: commonalities and disconnects. Patient Prefer Adherence. 2021;15:99\u2013110.","journal-title":"Patient Prefer Adherence"},{"issue":"22","key":"12589_CR30","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1182\/bloodadvances.2023010879","volume":"7","author":"C Tam","year":"2023","unstructured":"Tam C, Pinilla-Ibarz J, Castillo CG, Fenili AC, Huntley K, Karakus V, Mattar M, Miroli MA, Moura C, Pavlovsky M, et al. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL. Blood Adv. 2023;7(22):6819\u201328.","journal-title":"Blood Adv"},{"issue":"4","key":"12589_CR31","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/bjh.18306","volume":"198","author":"SP Mulligan","year":"2022","unstructured":"Mulligan SP, Opat S, Marlton P, Kuss B, Gerungan P, Puig A, McGeachie M, Tam CS. Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. Br J Haematol. 2022;198(4):790\u20133.","journal-title":"Br J Haematol"},{"issue":"4","key":"12589_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/tbm\/ibac099","volume":"13","author":"CL Bylund","year":"2023","unstructured":"Bylund CL, Eggly S, LeBlanc TW, Kurtin S, Gandee M, Medhekar R, Fu A, Khurana M, Delaney K, Divita A, et al. Survey of patients and physicians on shared decision-making in treatment selection in relapsed\/refractory multiple myeloma. Transl Behav Med. 2023;13(4):255\u201367.","journal-title":"Transl Behav Med"},{"issue":"2","key":"12589_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/tbm\/ibx034","volume":"8","author":"GB Rocque","year":"2018","unstructured":"Rocque GB, Williams CP, Halilova KI, Borate U, Jackson BE, Van Laar ES, Pisu M, Butler TW, Davis RS, Mehta A, et al. Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education. Transl Behav Med. 2018;8(2):175\u201382.","journal-title":"Transl Behav Med"},{"issue":"6","key":"12589_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3322\/caac.21245","volume":"64","author":"HL Kane","year":"2014","unstructured":"Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA. Implementing and evaluating shared decision making in oncology practice. CA Cancer J Clin. 2014;64(6):377\u201388.","journal-title":"CA Cancer J Clin"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12589-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:04:37Z","timestamp":1720706677000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12589-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12589"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12589-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Human Research Ethics Committee, Bellberry Limited on 23rd June 2022, Application number: 2022-05-448. All participants in the study provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S Fifer and J Godsell are employees of CaPPRe. CaPPRe has consulted to AbbVie, Amgen, AstraZeneca, Celgene, CSL Behring, Edwards, GSK, Ipsen, Janssen, Novo Nordisk, Roche, Sanofi, Shire and UCB, outside of the submitted work. S Opat has received research funding, honoraria and consulted to AbbVie, AstraZeneca, BeiGene, CSL Behring, Gilead, Ipsen, Janssen, Merck and Roche. N Hamad has received honoraria from AbbVie, AstraZeneca, BeiGene, CSL Gilead, Genentech, Janssen, Novartis and Roche. A Puig and M McGeachie are employees of Janssen-Cilag Australia Pty Ltd\u00a0(a Johnson and Johnson company). The authors report no other competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"831"}}